IDEAYA Biosciences is a precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapies for molecularly defined solid tumors. The company’s pipeline centers on synthetic lethality and antibody-drug conjugates, with its lead candidate darovasertib, an oral protein kinase C inhibitor, in late-stage clinical trials for uveal melanoma. Other clinical focus areas include antibody-drug conjugate and DNA damage response combinations, the MTAP pathway, and next-generation therapies such as KAT6/7 inhibitors. IDEAYA collaborates with pharmaceutical partners including Pfizer, Servier, Hengrui Pharma, and Gilead to support clinical development and commercialization. Servier holds exclusive rights to develop and commercialize darovasertib outside the United States, while IDEAYA retains rights in the U.S. market. The company targets patients with limited treatment options, utilizing predictive biomarkers to identify candidates for its precision oncology programs.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage ideayabio.com
Sector Healthcare IR page ir.ideayabio.com
Tags
precision oncology, uveal melanoma, small-molecule inhibitors, antibody-drug conjugates, synthetic lethality, protein kinase c inhibition, mtap pathway, kat6/7 inhibition, solid tumors, clinical-stage therapeutics, Darovasertib, OptimUM-02, OptimUM-01, OptimUM-10, OptimUM-09, OptimUM-11, Pfizer, Servier, Hengrui Pharma, Gilead
Press page ir.ideayabio.com/news-releases

Metrics

Valuation  
Market cap $ 3.656B
Market cap (USD) $ 3.656B
P/E -8.48
PEG —
P/BV 3.35
P/S 16.72
P/OCF -10.52
P/FCF -10.45
Dividend yield —
Turnover / mcap —
Returns  
ROE -10.9%
ROI -12.1%
ROIC -12.7%
Profit margin -52.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 68
Quality score -58.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 218.71M 7M 23.385M 50.931M 27.941M 19.538M — —
Net profit -113.698M -274.477M -112.961M -58.655M -49.762M -34.495M -41.975M -34.346M
Free cash flow -73.466M -251.441M -117.592M -90.618M -58.423M 54.97M -40.666M -29.328M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 34.57 25.7 35.58 18.17 23.64 14 7.5 —
Price performance 12m 0.35 -0.28 0.96 -0.23 0.69 0.87 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 1.88M 1.1M 211,000 18,000 3,000 —
↳ YoY growth -41.2% -80.9% -91.5% -83.3%
Lease liabilities (USD) — — 8M 6.77M 6.72M 5.18M 3.48M 2.87M 19.2M 27.9M
Cash and deposits (USD) 9.69M 6.03M 20.5M 34.1M 72M 92M 68.6M 157M 84.4M 113M
Right-of-use assets (USD) — — 6.1M 5.06M 5.21M 3.9M 2.48M 2.25M 18.8M 23.1M
Cash flow detail
Operating cash flow (USD) — -12.2M -27.6M -39.3M 55.5M -55.8M -87.2M -115M -248M -71.1M
Purchases of property, plant and equipment (USD) — -1.76M -1.71M -1.35M -493,000 -2.64M -3.44M -2.37M -3.86M -2.37M
Change in receivables (cash effect) (USD) — — — 0.00 -1.88M 774,000 892,000 193,000 15,000 0.00
Change in payables (cash effect) (USD) — 254,000 322,000 -195,000 225,000 1.17M 1.86M 2.64M 8.28M 2.7M
Interest paid (cash effect) (USD) — -19,000 -99,000 -91,000 -82,000 -71,000 -60,000 -69,000 -25,000 0.00
Income taxes paid (cash effect) (USD) — — -1,000 -1,000 -1,000 -4,000 0.00 0.00 — —
Share-based compensation (USD) — 136,000 950,000 2.17M 3.61M 8.24M 11.6M 18.5M 34.7M 46.1M
Operating cash flow before change in receivables (USD) — — — -39.3M 57.3M -56.6M -88.1M -115M -248M -71.1M
Free cash flow (OCF - PPE - intangibles) (USD) — -14M -29.3M -40.7M 55M -58.4M -90.6M -118M -251M -73.5M
Income detail
Research and development expense (USD) — 12.4M 31.7M 34.3M 39.7M 58.2M 89.5M 130M 295M 315M
↳ 5y CAGR +48.5% +32.5% +53.7% +51.3%
Total comprehensive income (USD) — -11.9M -34.4M -41.9M -34.6M -50.5M -60.8M -110M -274M -112M
Comprehensive income to owners (USD) — -11.9M -34.4M -41.9M -34.6M -50.5M -60.8M -110M -274M -112M
Reported Mar 24, 2020 Mar 24, 2020 Mar 24, 2020 Mar 18, 2022 Mar 23, 2021 Mar 18, 2022 Mar 7, 2023 Feb 20, 2024 Feb 18, 2025 Feb 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire / -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its participation in the upcoming investor relations events.

UBS Global Biopharma Conference
Monday, November 16, 2026 | 10:40 AM GMT (5:40 AM EST) | London, United Kingdom

  • Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer. The discussion will be hosted by Michael Yee, Global Head of Biotechnology Research and Managing Director, Senior Biotechnology and Pharma Analyst.

IDEAYA Biosciences Investor R&D Day
Monday, November 16, 2026 | 5:00 PM GMT (12:00 PM EST) | London, United Kingdom

The event will provide an overview of:

  • IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, including Phase 1 dose escalation clinical data summary of pharmacokinetics, safety, and human plasma SDMA pharmacodynamics
  • RAS progress, including breakthroughs, emerging data, and future challenges
  • Preclinical data supporting IDEAYA's broad clinical combination strategies targeting MTAP/CDKN2A and RAS-driven PDAC, NSCLC, and CRC, including IDE892 (PRMT5, Phase 1) in RAS-mutant PDAC, CDKN2A (target IND in H1 2027) in RAS-mutant PDAC and NSCLC, and IDE574 (KAT6/7, Phase 1) to intercept epigenetic alterations that drive resistance in RAS-mutant CRC and NSCLC
  • Target 2027 clinical data updates and milestones in MTAP/CDKN2A and KRAS, including PRMT5 and pan-RAS clinical combination

The event will feature Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center.

Advance registration is required for both in-person and virtual attendance. To register, please visit: https://lifescievents.com/event/izl51pw/

Jefferies Global Healthcare Conference
Tuesday, November 17, 2026 | 1:00 PM GMT (8:00 AM EST) | London, United Kingdom

  • Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer; Michael White, President of Research and Development; and Joshua Bleharski, Chief Financial Officer. The discussion will be hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology.

A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events  and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding IDEAYA's planned participation in investor conferences and its Investor R&D Day, including the timing, format, anticipated participants and content of these events; the timing and content of anticipated preclinical and clinical data presentations and updates; the potential best-in-class profile of IDE892; IDEAYA's development plans and combination strategies targeting MTAP/CDKN2A- and RAS-driven cancers, including the potential therapeutic benefits of these strategies; the timing of anticipated investigational new drug application submissions, including the targeted submission in the first half of 2027 for IDEAYA's CDKN2A program; anticipated clinical data updates and development milestones in 2027; and the availability of live and archived webcasts. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including uncertainties inherent in preclinical and clinical development; the risk that early preclinical or clinical results may not predict future clinical results; uncertainties regarding the safety, efficacy and differentiation of IDEAYA's product candidates, alone or in combination; and potential delays in clinical trials, data availability, regulatory submissions or regulatory clearances. Additional risks and uncertainties are described under "Risk Factors" and elsewhere in IDEAYA's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on February 17, 2026, and subsequent SEC filings. Forward-looking statements speak only as of the date of this press release. IDEAYA undertakes no obligation to update any forward-looking statement, except as required by law.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
[email protected]

SOURCE IDEAYA Biosciences, Inc.

Footer Logo

IDEAYA Biosciences logo with a rainbow DNA strand.

AI Link Title

Ask AI for a summary of this page

AI Links

Footer Link Column 1

ABOUT

Management Team

Board of Directors

Scientific Advisory Board

Footer Link Column 2

SCIENCE

PIPELINE

CLINICAL TRIALS

IDEAYA IDEAS

NEWSROOM

CAREERS

CONTACT

Footer Link Column 3

INVESTORS

Investors Overview

Overview

News Releases

Events

Stock Information

Corporate Governance

Financial Information

Investor Resources

AI Link Title

Ask AI for a summary of this page

AI Links

© 2026 IDEAYA BIOSCIENCES, INC. ALL RIGHTS RESERVED. 
"IDEAYA" is a registered trademark of IDEAYA Biosciences, Inc. MAT-0035 05/26

Privacy

Terms of Use

Accessibility Statement

(opens in a new window)

  • Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disease, irrespective of HLA-A*02:01 allele status or line of therapy

  • Completed NDA submission in Q3'26 to support the potential U.S. approval of darovasertib plus crizotinib in metastatic uveal melanoma

  • Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) presented at ESMO 2026 demonstrates robust anti-tumor activity and encouraging survival benefit in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC); initial data from IDEAYA-sponsored global Phase 1/2 trial expected by the end of 2026 / early 2027

  • IDEAYA R&D Day scheduled for November 16th to highlight preclinical data supporting rational combinations that exploit MTAP/CDKN2A deficiency in KRAS-mutant cancers

  • $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026; cash runway guidance into 2030 remains unchanged based on current operating plan

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2026 /PRNewswire / -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

"We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for darovasertib in metastatic uveal melanoma," said Yujiro S. Hata, Chief Executive Officer of IDEAYA.  "We also provided multiple clinical data updates at ESMO on darovasertib to support its potential as a foundational therapy across the entire uveal melanoma treatment journey as well as updated data from IDE849, our DLL3 TOP1 ADC, in relapsed SCLC and NEC.  Looking ahead, we are excited to share new preclinical data on our extensive MTAP/CDKN2A franchise in RAS-mutant cancers that provides the scientific rationale in support of the two clinical collaborations we established with Roche and Genentech."

Selected Pipeline Developments and Corporate Updates

Darovasertib for Uveal Melanoma (UM)

  • IDEAYA presented clinical data from two ongoing clinical trials in metastatic UM (mUM) at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.  The OptimUM-01 update focused on the Phase 2 expansion results in 101 HLA-A*02:01-positive patients, including both treatment naïve and 2L patients who received prior tebentafusp.  The OptimUM-02 update builds on positive topline data reported in June showing treatment naïve HLA-A*02:01-negative patients receiving darovasertib plus crizotinib (the darovasertib combination) had a meaningful and statistically significant improvement in median progression free survival (PFS) compared to investigator's choice of therapy as determined by both blinded independent central review (BICR) and investigator assessment.  Collectively, the data support the broad potential of the darovasertib combination to drive meaningful clinical benefits for patients with mUM, irrespective of HLA-A*02:01 allele status or line of therapy.
  • During the third quarter IDEAYA successfully submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to support a potential U.S. approval of the darovasertib combination in mUM under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program.
  • In primary UM, IDEAYA provided follow-up data at ESMO 2026 from approximately 119 patients enrolled in the Phase 2 OptimUM-09 trial evaluating single-agent darovasertib as a neoadjuvant therapy.  Consistent with prior results, >85% of patients treated with darovasertib experienced robust tumor shrinkage, resulting in a 57% eye preservation rate in the enucleation cohort and 74-79% of patients in the plaque brachytherapy cohort achieving a reduced predicted dose of radiation to critical eye structures including the fovea, disc center and lens.   
  • Due to ongoing site activation and enrollment challenges, IDEAYA has decided to stop enrollment and close the Phase 3 OptimUM-010 trial. This is expected to result in estimated cost savings of $100-125 million that the company will reallocate towards other high-value programs in its pipeline, including potential registrational trials for IDE849 and IDE892.
    • IDEAYA is committed to enabling patient access to neoadjuvant darovasertib and plans to submit published data from OptimUM-09 to support potential inclusion in clinical practice guidelines.  If successful, guideline inclusion is intended to provide evidence to support the potential clinical benefit of neoadjuvant darovasertib and may allow payor coverage for eligible patients in the United States. 
  • Following completion of a Type C meeting with the FDA earlier this year, IDEAYA and its partner, Les Laboratoires Servier (Servier), initiated a global Phase 3 registrational trial (OptimUM-011) to evaluate the darovasertib combination in the adjuvant setting of primary uveal melanoma. The trial is expected to enroll approximately 450 patients with increased risk of metastasis, irrespective of HLA status, randomized 1:1 to either 12-months of treatment with the combination or observation.  The primary endpoint of the trial is relapse-free survival.

Antibody-drug conjugates (ADCs)

  • IDE849 (DLL3 TOP1 ADC): IDEAYA's partner, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), provided a clinical update at ESMO 2026 from its Phase 1 trial in China evaluating IDE849 in patients with relapsed SCLC and NEC.  The data showed substantial anti-tumor activity together with more mature PFS results and encouraging survival outcomes, including median overall survival (OS) of 17.4 months in the 2L SCLC setting. The update also included data from 19 patients with other NECs, showing an ORR and confirmed ORR of 52.6% (10/19; 95% CI: 28.9–75.6) and 36.8% (7/19; 95% CI: 16.3–61.6), respectively, a median PFS of 7.0 months and nine-month OS rate of 82.4%.  IDEAYA plans to provide the first clinical data from its global Phase 1/2 trial of IDE849 monotherapy in extensive-stage SCLC (ES-SCLC) and NEC by the end of 2026 or early in 2027.
    • Following successful Type C meetings with the U.S. FDA, IDEAYA plans to initiate two Phase 3 registrational trials with IDE849 in ES-SCLC and NEC by year end.
    • The ES-SCLC trial will enroll 400 patients with prior tarlatamab treatment, randomized 1:1 to IDE849 or investigator's choice of therapy. The primary endpoint for accelerated approval will be ORR by BICR, and median OS for full approval. Secondary endpoints will include median DOR by BICR, PFS, and safety.  Details of the design of the Phase 3 trial in NEC will be provided at a later date.
  • IDE161 (PARG): IDEAYA is also evaluating a Phase 1 combination cohort of IDE849 with IDE161, a potential first-in-class poly(ADP-ribose) glycohydrolase (PARG) inhibitor in patients with ES-SCLC, NEC and other DLL3-overexpressing solid tumors.  IDEAYA has previously shared preclinical data demonstrating the mechanism of action of IDE161 in combination with TOP1-payload based ADCs in driving enhanced anti-tumor activity.
  • IDE034 (B7H3/PTK7 bispecific TOP1 ADC): IDEAYA plans to provide initial clinical data from its ongoing Phase 1 dose escalation trial in 2027, which is expected to include preliminary safety and efficacy data.  IDE034 is a potentially first-in-class B7H3/PTK7 bispecific TOP1 ADC designed to be internalized only when its target antigens are co-expressed on the same tumor cell, which may enhance its selectivity and tolerability profile relative to monovalent antibody formats.

MTAP pathway

  • IDE892 (PRMT5): monotherapy expansion has been initiated in the Phase 1 clinical trial evaluating IDE892 in MTAP-deleted solid tumors, with a focus on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).  The expansion has been initiated at projected efficacious target human exposures where 24-hour target EC90 coverage has been achieved.  The IDE892 maximum tolerated dose has not yet been reached in the ongoing dose escalation.  Pursuant to the clinical collaboration announced with Roche in May, IDEAYA is also targeting initiation of a Phase 1 trial to evaluate IDE892 in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant PDAC by the end of 2026.
    • In August, IDEAYA entered into a Clinical Supply Collaboration Agreement with Genentech to evaluate IDE892 in combination with RG6620, a Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant PDAC.  Genentech will sponsor and conduct the trial and IDEAYA will provide clinical supply of IDE892.
  • IDE397 (MAT2A): a Phase 1/2 combination cohort was initiated to evaluate IDE892 with IDE397, IDEAYA's proprietary MAT2A inhibitor, in MTAP-deleted cancers.  Expansion is planned by the first half of 2027 with an initial clinical focus on MTAP-deleted NSCLC.  Dual inhibition of MAT2A and PRMT5 has demonstrated durable tumor regressions in several preclinical MTAP-deleted tumor models, including NSCLC.

KAT6/7

  • IDE574 (KAT6/7): a Phase 1 dose escalation trial is underway in solid tumors including breast, prostate, colorectal and lung cancer.  In October, IDEAYA dosed its first patient in a Phase 1 combination cohort of IDE574 with fulvestrant in estrogen receptor positive (ER+) metastatic breast cancer.  IDE574 is a selective, equipotent dual inhibitor of both KAT6 and KAT7 which spares other structurally similar paralogs, including KAT5 and KAT8, which are required for normal cell function. KAT6 and KAT7 are epigenetic modulators of cell identity and lineage commitment programs that are corrupted by oncogenic transformation.

Corporate

  • IDEAYA will host an R&D Day on November 16, 2026 in London, United Kingdom to present new preclinical data highlighting IDEAYA's precision medicine pipeline and the opportunity to exploit MTAP/CDKN2A deficiency to greatly enhance the anti-tumor activity of pan-RAS and mutant-specific RAS inhibitors in KRAS-mutant cancers.  Dr. Frank McCormick, Professor of the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco will join members of the management team for the discussion.  Topics will include multiple rational combination strategies to target the underlying tumor heterogeneity and adaptive plasticity in KRAS cancers including PDAC, NSCLC, and colorectal cancer.
  • IDEAYA announced the promotion of Dr. Michael White, Ph.D. to President, Research and Development.  Dr. White had served as Chief Scientific Officer at IDEAYA Biosciences since 2021.  Prior to IDEAYA, Dr. White served as Chief Scientific Officer and Head of Tumor Biology at Pfizer, Inc., where he led cross-disciplinary groups in research and development to build an oncology small-molecule clinical pipeline focused on first-in-class therapies, culminating in numerous INDs and late-stage development programs. Prior to joining Pfizer, Dr. White had a prolific academic career of more than 20 years at UT Southwestern where he was a Professor of Cell Biology and founding Director of the Cancer Intervention and Prevention Discovery Program.

Third Quarter 2026 Financial Results

As of September 30, 2026, IDEAYA had cash, cash equivalents and marketable securities of approximately $1.15 billion, compared to $1.24 billion as of June 30, 2026. The decrease was primarily driven by net cash used in operations. IDEAYA's cash runway guidance into 2030 is unchanged based on the current operating plan.

Collaboration revenue for the three months ended September 30, 2026, totaled $10.2 million, compared to $8.9 million for the three months ended June 30, 2026. Collaboration revenue was recognized for the performance obligations satisfied through September 30, 2026 related to the research and development services that are recognized over time under the Servier exclusive license agreement for darovasertib. As of September 30, 2026, the remaining balance for the research and development services performance obligations is $139.8 million related to the clinical development cost reimbursements anticipated under the license agreement that will be recognized as IDEAYA collaboration revenue over time as the research and development services are completed.

Research and development (R&D) expenses for the three months ended September 30, 2026 totaled $121.6 million, compared to $108.7 million for the three months ended June 30, 2026. The increase was primarily driven by higher clinical trial and development costs and personnel-related expenses to support IDEAYA's programs.

General and administrative (G&A) expenses for the three months ended September 30, 2026 totaled $26.3 million, compared to $22.5 million for the three months ended June 30, 2026. The increase was primarily due to higher personnel-related expenses to support company growth and darovasertib commercial preparation activities.

The net loss for the three months ended September 30, 2026, was $125.7 million compared to the net loss of $112.5 million for the three months ended June 30, 2026. Total stock-based compensation expense for the three months ended September 30, 2026, was $17.7 million compared to $16.7 million for the three months ended June 30, 2026.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding darovasertib's development and potential clinical benefits, alone and in combination with crizotinib; the interpretation and potential implications of results from OptimUM-01, OptimUM-02 and OptimUM-09; the timing, conduct and outcome of the FDA's review of the NDA for the darovasertib combination in metastatic uveal melanoma, including under the RTOR program, and the potential approval and commercialization of darovasertib; the design, enrollment, timing and potential results of OptimUM-011; the closure of OptimUM-010, the anticipated cost savings therefrom, and the reallocation of such resources to other programs; the timing of initial clinical data from the global Phase 1/2 trial of IDE849, the planned initiation, design, and endpoints of Phase 3 registrational trials of IDE849, and the potential of IDE849 in SCLC and NEC; the development, timing of data and potential of IDE161, IDE034, IDE892, IDE397 and IDE574, including planned combination cohorts, expansions and trial initiations; IDEAYA's clinical collaborations; IDEAYA's cash runway and the sufficiency of its cash, cash equivalents and marketable securities to fund its operating plan; the possibility of establishing a new standard of care; potential effects on eye preservation and visual outcomes; and future clinical studies and data presentations. These statements reflect current expectations and involve risks and uncertainties, and actual results may differ materially from those expressed or implied. Clinical findings may change with additional follow-up, and early results, small cohorts and subgroup analyses may not predict outcomes in larger or subsequent studies. Factors that could cause actual results to differ include, among others, risks related to drug development, regulatory review and approval, clinical trial site activation and enrollment, manufacturing, reliance on collaborations, commercialization, the sufficiency of IDEAYA's capital resources, changes in IDEAYA's operating plan and macroeconomic conditions. Additional information about risks is available in IDEAYA's most recent Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and its other filings with the Securities and Exchange Commission. IDEAYA does not undertake to update these statements, except as required by law.

Investor and Media Contact

IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
[email protected]

IDEAYA Biosciences, Inc. Condensed Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts)
Three Months Ended Nine Months Ended
September 30, 2026 June 30, 2026 September 30, 2026 September 30, 2025
(Unaudited) (Unaudited)
Collaboration revenue $ 10,242 $ 8,857 $ 25,660 $ 207,834
Operating expenses:
Research and development 121,576 108,689 325,991 228,105
General and administrative 26,298 22,459 68,135 44,472
Total operating expenses 147,874 131,148 394,126 272,577
Loss from operations (137,632) (122,291) (368,466) (64,743)
Interest income and other income, net 11,883 9,839 31,726 34,318
Net loss (125,749) (112,452) (336,740) (30,425)
Unrealized (losses) gains on marketable securities (3,214) (1,176) (7,151) 1,240
Comprehensive loss $ (128,963) $ (113,628) $ (343,891) $ (29,185)
Net loss per share    attributable to common    stockholders, basic $ (1.22) $ (1.22) $ (3.56) $ (0.34)
Weighted-average number of shares   outstanding, basic 102,944,175 92,061,452 94,620,638 88,452,395
Net loss per share    attributable to common    stockholders, diluted $ (1.22) $ (1.22) $ (3.56) $ (0.34)
Weighted-average number of shares   outstanding, diluted 102,944,175 92,061,452 94,620,638 88,452,395
IDEAYA Biosciences, Inc. Condensed Balance Sheet Data (in thousands)
September 30, December 31,
2026 2025
(Unaudited)
Cash and cash equivalents and short-term and long-term marketable securities $ 1,150,827 $ 1,049,685
Total assets 1,216,020 1,109,324
Total liabilities 123,957 86,390
Total liabilities and stockholders' equity $ 1,216,020 $ 1,109,324

SOURCE IDEAYA Biosciences, Inc.

Footer Logo

IDEAYA Biosciences logo with a rainbow DNA strand.

AI Link Title

Ask AI for a summary of this page

AI Links

Footer Link Column 1

ABOUT

Management Team

Board of Directors

Scientific Advisory Board

Footer Link Column 2

SCIENCE

PIPELINE

CLINICAL TRIALS

IDEAYA IDEAS

NEWSROOM

CAREERS

CONTACT

Footer Link Column 3

INVESTORS

Investors Overview

Overview

News Releases

Events

Stock Information

Corporate Governance

Financial Information

Investor Resources

AI Link Title

Ask AI for a summary of this page

AI Links

© 2026 IDEAYA BIOSCIENCES, INC. ALL RIGHTS RESERVED. 
"IDEAYA" is a registered trademark of IDEAYA Biosciences, Inc. MAT-0035 05/26

Privacy

Terms of Use

Accessibility Statement

(opens in a new window)

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire / -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today announced that, on October 29, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 99,600 shares of the Company's common stock to four newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $32.89 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer 
[email protected]

SOURCE IDEAYA Biosciences, Inc.

Footer Logo

IDEAYA Biosciences logo with a rainbow DNA strand.

AI Link Title

Ask AI for a summary of this page

AI Links

Footer Link Column 1

ABOUT

Management Team

Board of Directors

Scientific Advisory Board

Footer Link Column 2

SCIENCE

PIPELINE

CLINICAL TRIALS

IDEAYA IDEAS

NEWSROOM

CAREERS

CONTACT

Footer Link Column 3

INVESTORS

Investors Overview

News Releases

Events

Stock Information

Corporate Governance

Financial Information

Investor Resources

AI Link Title

Ask AI for a summary of this page

AI Links

© 2026 IDEAYA BIOSCIENCES, INC. ALL RIGHTS RESERVED. 
"IDEAYA" is a registered trademark of IDEAYA Biosciences, Inc. MAT-0035 05/26

Privacy

Terms of Use

Accessibility Statement

(opens in a new window)

Prompts

IDEAYA Biosciences, Inc. (ticker IDYA), listed in United States.

ETFs Holding IDEAYA Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
CANC 2.70% 142,271 $ 5.705M Aug 31, 2026
ILDR 0.53% 55,538 $ 1.686M Nov 16, 2026
SEIS 0.22% 33,963 $ 1.266M Jun 30, 2026
AVSC 0.19% 200,352 $ 6.083M Nov 16, 2026
FFF 0.14% 238 $ 9,143.96 Sep 30, 2026
RESM 0.10% 97 $ 3,615.19 Jun 30, 2026
FSEG 0.07% 104 $ 3,876.08 Jun 30, 2026
DFAS 0.06% 620,157 $ 19.529M Nov 12, 2026
FESM 0.04% 66,750 $ 2.488M Jun 30, 2026
MSSM 0.02% 4,078 $ 163.528K Aug 31, 2026
DXUV 0.02% 35,993 $ 1.133M Nov 12, 2026
DFAC 0.01% 351,452 $ 11.067M Nov 12, 2026
DCOR 0.01% 91,394 $ 2.878M Nov 12, 2026
DFSU 0.01% 4,381 $ 137.958K Nov 12, 2026
DFAU 0.01% 21,463 $ 675.87K Nov 12, 2026
DFUS 0.00% 32,185 $ 1.014M Nov 12, 2026
AVUS 0.00% 14,405 $ 437.336K Nov 16, 2026